- Home
- CCEL vs IGC Comparison
CCEL vs IGC Comparison
Compare CCEL & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- IGC
- Stock Information
- Founded
- CCEL 1989
- IGC 2005
- Country
- CCEL United States
- IGC United States
- Employees
- CCEL N/A
- IGC N/A
- Industry
- CCEL Managed Health Care
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- IGC Health Care
- Exchange
- CCEL Nasdaq
- IGC Nasdaq
- Market Cap
- CCEL 39.9M
- IGC 33.5M
- IPO Year
- CCEL 1997
- IGC N/A
- Fundamental
- Price
- CCEL $4.90
- IGC $0.34
- Analyst Decision
- CCEL Strong Buy
- IGC Strong Buy
- Analyst Count
- CCEL 1
- IGC 2
- Target Price
- CCEL $8.50
- IGC $3.88
- AVG Volume (30 Days)
- CCEL 7.1K
- IGC 1.1M
- Earning Date
- CCEL 07-15-2025
- IGC 08-15-2025
- Dividend Yield
- CCEL 12.50%
- IGC N/A
- EPS Growth
- CCEL N/A
- IGC N/A
- EPS
- CCEL N/A
- IGC N/A
- Revenue
- CCEL $31,988,783.00
- IGC $1,271,000.00
- Revenue This Year
- CCEL $1.75
- IGC $15.26
- Revenue Next Year
- CCEL N/A
- IGC $3.41
- P/E Ratio
- CCEL N/A
- IGC N/A
- Revenue Growth
- CCEL 1.10
- IGC N/A
- 52 Week Low
- CCEL $4.68
- IGC $0.25
- 52 Week High
- CCEL $9.43
- IGC $0.48
- Technical
- Relative Strength Index (RSI)
- CCEL 48.00
- IGC 46.47
- Support Level
- CCEL $4.75
- IGC $0.35
- Resistance Level
- CCEL $5.43
- IGC $0.36
- Average True Range (ATR)
- CCEL 0.26
- IGC 0.02
- MACD
- CCEL 0.01
- IGC -0.01
- Stochastic Oscillator
- CCEL 28.38
- IGC 11.87
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.